Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2013 by Universitaire Ziekenhuizen Leuven
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven Identifier:
First received: August 16, 2011
Last updated: March 1, 2013
Last verified: February 2013

The goal of this study is to calculate pharmacokinetic parameters and to evaluate the trough levels of posaconazole reached in patients with different stages of mucositis, due to chemotherapy and total body irradiation.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis

Resource links provided by NLM:

Further study details as provided by Universitaire Ziekenhuizen Leuven:

Primary Outcome Measures:
  • Posaconazole plasma levels and area under the curve in patients with different stages of mucositis [ Time Frame: Day 0 (day of transplantation), day +7, day +14, day +21, day +28 and day +35 ] [ Designated as safety issue: No ]
    Plasma levels of posaconazole will be determined to calculate the area under the curve. These values will be correlated with the stage of mucositis, which will be assessed using citrulline monitoring in plasma. The stage of mucositis will also be assessed using the Daily Oral Mucositis Score (DMS) and Daily Gut Mucositis Score (DGS).

Estimated Enrollment: 20
Study Start Date: September 2011
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients on the hematology ward who will receive an allogeneic stem cell transplantation.


Inclusion Criteria:

  • Patients receiving allogeneic stem cell transplantation - Treated with prophylactic posaconazole 200mg three times daily to prevent invasive fungal infections

Exclusion Criteria:

  • Gastroparesis
  • Vomiting or diarrhea within 2 hours after intake of posaconazole
  • Concomitant administration of potent inducers of the enzyme UGT1A4: carbamazepine,phenytoin, phenobarbital, rifabutin, rifampicin,...
  • Age under 18 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01420562

Contact: Kim Vanstraelen, R.Ph. (+32) (0)16342339
Contact: Isabel Spriet, Pharm.D.

University Hospitals Leuven Recruiting
Leuven, Vlaams-Brabant, Belgium, 3000
Principal Investigator: Kim Vanstraelen, R.Ph.         
Sub-Investigator: Isabel Spriet, Pharm.D.         
Sub-Investigator: Ludo Willems, Professor         
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Principal Investigator: Kim Vanstraelen, R.Ph. Catholic University of Leuven, Faculty of Pharmacy, division Hospital Pharmacy
  More Information

No publications provided

Responsible Party: Universitaire Ziekenhuizen Leuven Identifier: NCT01420562     History of Changes
Other Study ID Numbers: ML7267
Study First Received: August 16, 2011
Last Updated: March 1, 2013
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by Universitaire Ziekenhuizen Leuven:
allogeneic HSCT

Additional relevant MeSH terms:
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Trypanocidal Agents
Antiprotozoal Agents
Antiparasitic Agents
14-alpha Demethylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 18, 2014